Apoa4-KO Mouse
一般名
Apoa4-KO
製品ID
S-KO-17081
背景情報
C57BL/6JCya
系統ID
KOCMP-11808-Apoa4-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Apoa4-KO Mouse（カタログ番号S-KO-17081）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Apoa4-KO
系統ID
KOCMP-11808-Apoa4-B6J-VB
遺伝子名
製品ID
S-KO-17081
遺伝子別名
Apoa-4
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 9
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000034585
NCBIトランスクリプトID
NM_007468.2
ターゲット領域
Exon 3
有効領域の大きさ
~2.1 kb
遺伝子研究の概要
Apoa4, also known as apolipoprotein A-IV, is a versatile apolipoprotein facilitating lipid transport and metabolism. It is synthesized in the small intestine, packaged onto chylomicrons, and secreted into intestinal lymph. Apoa4 may also be involved in anti-inflammatory responses [4]. It has been identified as a sphingosine 1-phosphate chaperone, supporting extracellular S1P signaling functions in the absence of ApoM and albumin [5]. A long non-coding RNA, APOA4-AS, has been shown to regulate ApoA4 expression depending on HuR in mice, and its knockdown leads to decreased levels of plasma triglyceride and total cholesterol in ob/ob mice [6].
Mutations in Apoa4 can cause autosomal dominant medullary amyloidosis, presenting as tubulointerstitial kidney disease with marked amyloid deposition limited to the kidney medulla [1]. Apoa4 may serve as a biomarker in several conditions. For example, serum APOA4 levels were found to be a pharmacodynamic marker of the recombinant human hepatocyte growth factor (E3112) [2], a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis [3], and a circulating marker for predicting the progression of renal impairment in T2DM patients [7]. APOA4 polymorphism was associated with an unfavorable lipid serum profile and depression in a cross-sectional study [8].
In conclusion, Apoa4 plays essential roles in lipid transport, metabolism, and anti-inflammatory responses. Its mutations can lead to kidney-related amyloidosis. The study of Apoa4 through various genetic models, as seen in some of the research, has provided insights into its function in different disease conditions, such as in kidney diseases, drug response, and certain skin and metabolic disorders.
References:
1. Kmochová, Tereza, Kidd, Kendrah O, Orr, Andrew, Bleyer, Anthony J, Kmoch, Stanislav. 2023. Autosomal dominant ApoA4 mutations present as tubulointerstitial kidney disease with medullary amyloidosis. In Kidney international, 105, 799-811. doi:10.1016/j.kint.2023.11.021. https://pubmed.ncbi.nlm.nih.gov/38096951/
2. Motoi, Sotaro, Uesugi, Mai, Obara, Takashi, Imai, Toshio, Kawano, Tetsu. 2021. Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112). In International journal of molecular sciences, 22, . doi:10.3390/ijms22094578. https://pubmed.ncbi.nlm.nih.gov/33925510/
3. Gong, Ting, Zhang, Peng, Ruan, Shi-Fan, Chung, Wen-Hung, Ji, Chao. 2023. APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts. In Journal of the American Academy of Dermatology, 89, 45-52. doi:10.1016/j.jaad.2023.02.058. https://pubmed.ncbi.nlm.nih.gov/36963506/
4. Zhang, Yupeng, He, Jing, Zhao, Jing, Li, Zongfang, Li, Xiaoming. 2017. Effect of ApoA4 on SERPINA3 mediated by nuclear receptors NR4A1 and NR1D1 in hepatocytes. In Biochemical and biophysical research communications, 487, 327-332. doi:10.1016/j.bbrc.2017.04.058. https://pubmed.ncbi.nlm.nih.gov/28412351/
5. Obinata, Hideru, Kuo, Andrew, Wada, Yukata, Izumi, Takashi, Hla, Timothy. 2019. Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice. In Journal of lipid research, 60, 1912-1921. doi:10.1194/jlr.RA119000277. https://pubmed.ncbi.nlm.nih.gov/31462513/
6. Qin, Wangshu, Li, Xinzhi, Xie, Liwei, Zhou, Yifa, Chen, Zheng. 2016. A long non-coding RNA, APOA4-AS, regulates APOA4 expression depending on HuR in mice. In Nucleic acids research, 44, 6423-33. doi:10.1093/nar/gkw341. https://pubmed.ncbi.nlm.nih.gov/27131369/
7. Cheng, Chao-Wen, Chang, Che-Chang, Chen, Hsiu-Wen, Lin, Ching-Yu, Chen, Jin-Shuen. 2018. Serum ApoA4 levels predicted the progression of renal impairment in T2DM. In European journal of clinical investigation, 48, e12937. doi:10.1111/eci.12937. https://pubmed.ncbi.nlm.nih.gov/29675916/
8. Ota, Vanessa Kiyomi, Chen, Elizabeth Suchi, Ejchel, Tatiana Flank, Burbano, Rommel Rodriguez, Smith, Marília de Arruda Cardoso. . APOA4 polymorphism as a risk factor for unfavorable lipid serum profile and depression: a cross-sectional study. In Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 59, 966-70. doi:10.2310/JIM.0b013e31822467cd. https://pubmed.ncbi.nlm.nih.gov/21712729/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。